Prognostic Factors of Radiofrequency Ablation plus Systemic Chemotherapy for Unresectable Colorectal Cancer with Liver Metastasis

Table 2

Estimated survival times by potential prognostic factor.

Variables		Median survival, months (95% CI)	value
Sex	Male ()	35 (27–42)	0.155
	Female ()	32 (27–39)
Age	<40 ()	40 (21–58)	0.66
	40–60 ()	32 (25–38)
	>60 ()	37 (31–42)
Number of liver lesions	1–3 ()	41 (35–48)	0.008
	4–5 ()	24 (19–29)
Size of the largest liver lesion	≤3 cm ()	38 (35–51)	0.026
	>3 cm ()	30 (15–44)
Sum of the diameter of liver lesions	<5 cm ()	43 (35–51)	0.011
	5–10 cm ()	30 (25–36)
	>10 cm ()	22 (16–27)
Primary cancer	Colon ()	40 (33–47)	0.263
	Rectum ()	28 (23–33)
Type of metastasis	Synchronous ()	32 (28–35)	0.69
	Metachronous ()	35 (29–50)
Chemo regimen	FOLFOX–4 ()	32 (23–46)	0.346
	FOLFIRI ()	28 (23–33)
ECOG performance status	0 ()	42 (36–49)	0.003
	I ()	24 (19–29)
Serum CEA	≤30 ng/mL ()	40 (33–46)	0.035
	>30 ng/mL ()	25 (20–30)

ECOG: Eastern Cooperative Oncology Group; CEA: carcinoembryonic antigen.